NEW YORK (GenomeWeb) – Merck and NanoString Technologies today announced a research collaboration to develop an assay to evaluate the potential benefits to a patient treated with Merck's anti-PD-1 therapy Keytruda (pembrolizumab).

The assay will be based on immune-related gene expression signatures and will be developed using NanoString's nCounter analysis system to optimize gene expression signatures as part of the clinical development of Keytruda.

Keytruda is a monoclonal antibody that blocks interaction between PD-1 and its ligands.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that researchers in Italy are testing a gene drive aimed at controlling mosquito populations.

Researchers may experience the effects of the government shutdown for a while, the Los Angeles Times reports.

A new study finds that the majority of patients at a Tijuana clinic received a diagnosis after first-line genome sequencing, the San Diego Union-Tribune reports.

In Genome Biology this week: post-transcriptional modification-based stratification of glioblastoma, single-cell analysis of gene expression and methylation in human iPSCs, and more.